Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04850560
Other study ID # IR2021001123
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 18, 2021
Est. completion date May 1, 2024

Study information

Verified date April 2021
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Hui Liu, MD, PhD
Phone 13819198629
Email sylenliu@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of CD19 PD-1/CD28-CAR-T sequential low-dose decitabine in the treatment of relapse or refractory B cell lymphoma.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date May 1, 2024
Est. primary completion date May 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - (1) Age = 18, upper limit 75, unlimited for men and women; (2) ECOG score 0-3; (3) Histologically confirmed diffuse large B-cell lymphoma (DLBCL) [according to who 2008]; (4) CD19 was positive (immunohistochemistry or flow cytometry). (5) The definition of refractory or relapse of DLBCL is: no complete remission after 2-line treatment; disease progression in any treatment process, or disease stabilization time equal to or less than 6 months; or disease progression or relapse within 12 months after hematopoietic stem cell transplantation; (6) The previous treatment of diffuse large B cell lymphoma must include rituximab (CD20 mAb) and anthracycline; (7) There should be at least one measurable focus. It is required that any length of lymph node focus should be greater than 1.5cm or any length of extranodal focus should be greater than 1.0cm. PET-CT scan focuses should have uptake (SUV is greater than liver blood pool); (8) The absolute value of neutrophils in peripheral blood = 1000 / µ L, platelet = 45000 / µ L; (9) Heart, liver and kidney function: creatinine < 1.5mg/dl; ALT (alanine aminotransferase) / AST (aspartate aminotransferase) 2.5 times lower than the normal upper limit; total bilirubin < 1.5mg/dl; heart ejection fraction (EF) = 50%; (10) Sufficient understanding ability and voluntary signing of informed consent; (11) Those with fertility must be willing to use contraceptive methods; (12) According to the judgment of the researchers, the expected survival time is more than 4 months; (13) Willing to follow visit schedule, administration plan, laboratory inspection and other test steps. Exclusion Criteria: - (1) History of other tumors; (2) Hematopoietic stem cell transplantation was performed within 6 weeks; (3) Any target car-t treatment was performed within 3 months before the car-t treatment; (4) Previous use of any commercially available PD-1 mAb; (5) Cytotoxic drugs, glucocorticoids and other targeted drugs were received within 2 weeks before cell collection; (6) Active autoimmune diseases; (7) Uncontrollable infection of active bacteria and fungi; (8) HIV infection, syphilis infection; active hepatitis B or C: hepatitis B: HBV-DNA = 1000IU / ml; hepatitis C: HCV RNA positive and liver function abnormal. (9) Known central nervous system lymphoma.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine
CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine

Locations

Country Name City State
China 2nd Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate Objective response rate of the combination 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05760196 - Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors Phase 2
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Recruiting NCT04670978 - Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer Phase 2
Recruiting NCT05310383 - Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Phase 2
Suspended NCT05503108 - Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer Phase 3
Recruiting NCT06125834 - Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy Phase 2
Recruiting NCT03892577 - Real-world Study for Patients With Advanced Hepatobiliary Tumors
Recruiting NCT04664244 - Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma Phase 2